Sunitinib, an anti-angiogenic drug, stimulates expression of VEGF-C by tumor cells and promotes lymphangiogenesis and LN metastasis in experimental and human ccRCC [141], suggesting that a therapy for inhibiting tumor blood vessels but inducing lymphatic growth may eventually result in treatment failure. Here, VEGFC is linked to neoplasm.